These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 38048588

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Combination therapy of rituximab and mycophenolate mofetil in childhood lupus nephritis.
    Hogan J, Godron A, Baudouin V, Kwon T, Harambat J, Deschênes G, Niel O.
    Pediatr Nephrol; 2018 Jan; 33(1):111-116. PubMed ID: 28780657
    [Abstract] [Full Text] [Related]

  • 3. Rituximab use as induction therapy for lupus nephritis: a systematic review.
    Stolyar L, Lahita RG, Panush RS.
    Lupus; 2020 Jul; 29(8):892-912. PubMed ID: 32486934
    [Abstract] [Full Text] [Related]

  • 4. Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis.
    Davies RJ, Sangle SR, Jordan NP, Aslam L, Lewis MJ, Wedgwood R, D'Cruz DP.
    Lupus; 2013 May; 22(6):574-82. PubMed ID: 23632989
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis.
    Basu B, Roy B, Babu BG.
    Pediatr Nephrol; 2017 Jun; 32(6):1013-1021. PubMed ID: 28191596
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Treatment outcomes in refractory lupus nephritis: Data from an observational study.
    Gururani S, Devarasetti PK, Uppin M, Rajasekhar L.
    Lupus; 2021 Oct; 30(11):1725-1731. PubMed ID: 34304627
    [Abstract] [Full Text] [Related]

  • 11. Immunosuppressive treatment for proliferative lupus nephritis.
    Tunnicliffe DJ, Palmer SC, Henderson L, Masson P, Craig JC, Tong A, Singh-Grewal D, Flanc RS, Roberts MA, Webster AC, Strippoli GF.
    Cochrane Database Syst Rev; 2018 Jun 29; 6(6):CD002922. PubMed ID: 29957821
    [Abstract] [Full Text] [Related]

  • 12. [Efficacy and safety of half-dose rituximab in the treatment of 23 cases with lupus nephritis].
    Zhao YR, Li KP, Deng XH, Liu XF, Liao SM, Yang JS, Zheng X, Zhang JL, Huang F, Zhu J.
    Zhonghua Nei Ke Za Zhi; 2023 Jan 01; 62(1):84-87. PubMed ID: 36631042
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of bortezomib in refractory lupus nephritis: a single-center experience.
    Segarra A, Arredondo KV, Jaramillo J, Jatem E, Salcedo MT, Agraz I, Ramos N, Carnicer C, Valtierra N, Ostos E.
    Lupus; 2020 Feb 01; 29(2):118-125. PubMed ID: 31865857
    [Abstract] [Full Text] [Related]

  • 14. Remission and long-term outcomes of proliferative lupus nephritis: retrospective study of 96 patients from Saudi Arabia.
    Almalki AH, Alrowaie FA, Alhozali HM, Almalki NK, Alsubei AI, Alturki MS, Sadagah LF.
    Lupus; 2019 Aug 01; 28(9):1082-1090. PubMed ID: 31296138
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Clinical efficacy and safety of rituximab in lupus nephritis.
    Zhong Z, Li H, Zhong H, Zhou T.
    Drug Des Devel Ther; 2019 Aug 01; 13():845-856. PubMed ID: 30880917
    [Abstract] [Full Text] [Related]

  • 17. Long-term renal survival of paediatric patients with lupus nephritis.
    Demir S, Gülhan B, Özen S, Çeleğen K, Batu ED, Taş N, Orhan D, Bilginer Y, Düzova A, Ozaltin F, Topaloğlu R.
    Nephrol Dial Transplant; 2022 May 25; 37(6):1069-1077. PubMed ID: 33826705
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.